Obesity drug effective for binge eating disorder
Reuters Health
Wednesday, February 6, 2008
NEW YORK (Reuters Health) - "Out of control" binge eaters may benefit from the appetite-suppressant drug sibutramine, based on a study showing that the drug reduces the number of binge eating episodes, along with weight and associated psychological illness.
Sibutramine appears to modify internal signals that control hunger and feelings of fullness, Dr. Denise E. Wilfley, of Washington University School of Medicine, St. Louis, Missouri, and colleagues report in the American Journal of Psychiatry.
Binge eaters often eat large amounts of food while feeling a loss of control over their eating. It is different from the binge-purge syndrome of bulimia because binge eaters do not purge afterward by vomiting or taking laxatives. Binge eating disorder is contributing to the rise in obesity.
In a study lasting 24 weeks, Wilfley's team examined the effects of sibutramine, compared with placebo, in 304 binge eaters. Overall, 289 of them had at least one post-randomization efficacy measure (sibutramine, n = 150; placebo, n = 139). Average adherence to study medication was 76.2 percent in the sibutramine group and 82.6 percent in the placebo group.
Binge eaters who received sibutramine had a significantly greater reduction in average weekly binge frequency compared to binge eaters who received placebo; in the sibutramine group, the frequency dropped from 3.3 binges per week to 0.6, compared with a drop from 3.4 to 1.3 in the placebo group.
Average weight loss was also greater in the sibutramine group than the placebo group (4.3 kg or 9.5 lbs versus 0.8 kg or 1.8 lbs).
Sibutramine-treated patients also had higher levels of overall improvement; however, no significant change in quality of life scores was observed between the groups. Side effects of sibutramine included headache, dry mouth, constipation, insomnia, and dizziness.
This placebo-controlled trial suggests that sibutramine may be effective in binge eaters, the researchers conclude.
SOURCE: American Journal of Psychiatry, January 2008
Reuters Health
Wednesday, February 6, 2008
NEW YORK (Reuters Health) - "Out of control" binge eaters may benefit from the appetite-suppressant drug sibutramine, based on a study showing that the drug reduces the number of binge eating episodes, along with weight and associated psychological illness.
Sibutramine appears to modify internal signals that control hunger and feelings of fullness, Dr. Denise E. Wilfley, of Washington University School of Medicine, St. Louis, Missouri, and colleagues report in the American Journal of Psychiatry.
Binge eaters often eat large amounts of food while feeling a loss of control over their eating. It is different from the binge-purge syndrome of bulimia because binge eaters do not purge afterward by vomiting or taking laxatives. Binge eating disorder is contributing to the rise in obesity.
In a study lasting 24 weeks, Wilfley's team examined the effects of sibutramine, compared with placebo, in 304 binge eaters. Overall, 289 of them had at least one post-randomization efficacy measure (sibutramine, n = 150; placebo, n = 139). Average adherence to study medication was 76.2 percent in the sibutramine group and 82.6 percent in the placebo group.
Binge eaters who received sibutramine had a significantly greater reduction in average weekly binge frequency compared to binge eaters who received placebo; in the sibutramine group, the frequency dropped from 3.3 binges per week to 0.6, compared with a drop from 3.4 to 1.3 in the placebo group.
Average weight loss was also greater in the sibutramine group than the placebo group (4.3 kg or 9.5 lbs versus 0.8 kg or 1.8 lbs).
Sibutramine-treated patients also had higher levels of overall improvement; however, no significant change in quality of life scores was observed between the groups. Side effects of sibutramine included headache, dry mouth, constipation, insomnia, and dizziness.
This placebo-controlled trial suggests that sibutramine may be effective in binge eaters, the researchers conclude.
SOURCE: American Journal of Psychiatry, January 2008